Eutilex.Co.,Ltd (KOSDAQ:263050)

South Korea flag South Korea · Delayed Price · Currency is KRW
2,140.00
+491.00 (29.78%)
At close: Jun 27, 2025, 3:30 PM KST
12.75%
Market Cap 78.82B
Revenue (ttm) 11.25B
Net Income (ttm) -27.74B
Shares Out 36.83M
EPS (ttm) -753.49
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 3,350,408
Average Volume 525,671
Open 1,649.00
Previous Close 1,649.00
Day's Range 1,646.00 - 2,140.00
52-Week Range 1,163.00 - 3,700.00
Beta 1.03
RSI 86.57
Earnings Date Aug 14, 2025

About Eutilex.Co.,Ltd

Eutilex.Co.,Ltd. engages in the discovery and development of immunomodulatory antibody therapeutics to treat cancers and autoimmune diseases. It develops EU101, a fully humanized anti-human 4-1BB monoclonal antibody; EU103, a fully humanized therapeutic monoclonal antibody; and EU501, an 4-1BB mAb-based, tumor antigen targeting bispecific antibodies. The company was founded in 2008 and is headquartered in Seoul, South Korea. [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 2008
Country South Korea
Stock Exchange KOSDAQ
Ticker Symbol 263050
Full Company Profile

Financial Performance

In 2024, Eutilex.Co.,Ltd's revenue was 9.53 billion, an increase of 7136.10% compared to the previous year's 131.65 million. Losses were -29.17 billion, 5.22% more than in 2023.

Financial Statements

News

There is no news available yet.